Fig. 4: Therapeutic efficacy of in the rhesus macaque model of SARS-CoV-2 infection. | Nature Communications

Fig. 4: Therapeutic efficacy of in the rhesus macaque model of SARS-CoV-2 infection.

From: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Fig. 4

a Experimental design for therapeutic testing of P4A1–2A in the rhesus macaque (n = 3/group). b Viral load in oropharyngeal swabs tested by RT-qPCR was monitored for 7 days. c Viral load in the respiratory tissues (including trachea, left and right bronchus, and all six lung lobes) collected at necropsy on 7 days post infection (d.p.i., n = 1/group) was tested by RT-qPCR. d Representative images of histopathology in lung tissue from isotype control or P4A1–2A 50 mg/kg treated animals (collected at 7 d.p.i., n = 1/group).

Back to article page